NCT06917742 - A Study of CPTX2309 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Healthy Volunteers

Interventions

DRUG

CPTX2309

Single Escalating Dose of CPTX2309. CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.

DRUG

CPTX2309

Multiple Escalating Dose of CPTX2309.CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.

Trial Locations (1)

4006

RECRUITING

Nucleus Network Brisbane, Herston